Tuesday, December 10, 2019 7:52:33 PM
You have a clear working knowledge of the stock, asset purchase agreement as well as the trials. You post is very well written and articulated. I contend you are a plant from Medivir, Batuta, one of the funds, or other entity possibly looking to scare shareholders. Very poor job if that is indeed your intention. The reality is the decline is end of year selling and a very small volume it is. With the trials moving along it will be interesting how those involved with the purchase agreement figure out how to raise capital to pay shareholders. I will add to my position based on your post. Thank you.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM